An interventional study of Urolithin A 500mg and Placebo in Obesity & Overweight, sponsored by Charles University, Czech Republic. Active, not recruiting at 1 site in Czechia. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Charles University, Czech Republic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Obesity with a site in Czechia — 26 open to participants now, 46 under way, 32 of them phase 3. Obesity · Czechia.
Among the 97 studies in Obesity with a site in Czechia, this one is the 62nd largest by enrollment of the 88 interventional ones that give a count, is one of 21 that started in 2025, is one of 33 with no phase, reaches primary completion later than 4 of the 45 other live ones, and was the 74th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →26 of the 97 studies in Obesity with a site in Czechia are open now. Recruiting first, the newest first:
Ascletis Pharma (China) Co., Limited · Sites in Czechia, United States, Canada and 4 more countries
Ages 18+
Ascletis Pharma (China) Co., Limited · Sites in Czechia, United States, Germany and 3 more countries
Ages 18+
AstraZeneca · Sites in Czechia, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in Czechia, United States, Argentina and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in Czechia, United States, Argentina and 24 more countries
Ages 18+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 478 across the 88 interventional studies, 200 across the 9 observational. Of the 44 that completed or were terminated, 14 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 97 have an industry lead sponsor. The 10 most frequent:
Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.
Charles University, Czech Republic has 7 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
16 of the studies in Obesity with a site in Czechia that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 16 to your calendar (.ics) → With an account.
Among the 97 studies in Obesity with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Purpose. This study will test whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive the same structured lifestyle program (nutrition and sleep guidance); half will receive Urolithin A and half a matching placebo.
Background. Weight loss can improve health but may also reduce skeletal muscle, especially in people with obesity. Aging and obesity are both linked to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation. Urolithin A is a gut-derived, diet-related compound that promotes mitophagy and may support muscle function and metabolic health.
Design. Single-center, randomized, placebo-controlled, parallel-group trial. About 100 adults aged 30-60 years with BMI >30 kg/m² and elevated visceral adiposity will be enrolled and randomized in a 1:1 ratio (stratified by sex and age ≤45 vs ≥45 years). Blinding will include participants, study staff, and assessors.
Intervention.
Urolithin A 500 mg orally once daily vs matching placebo, for 24 weeks.
A standardized lifestyle program for all participants: individualized energy restriction with higher protein intake, reduced carbohydrates, and time-restricted eating (11-hour eating window / 13-hour overnight fast); plus structured sleep-hygiene recommendations and light daily activity guidance.
No other dietary supplements are allowed during the study.
Main assessments. At baseline and regularly during the study, participants will undergo:
Body composition by bioimpedance (InBody), including skeletal muscle and visceral fat indices.
Muscle function (handgrip dynamometry; 30-second chair-stand).
Cardiometabolic and inflammatory biomarkers from blood (standard biochemistry, lipids, glucose/HbA1c, CRP; exploratory cytokines/adipokines).
Mitochondrial/aging biomarkers, including DNA-based epigenetic aging measures.
Cardiovascular/ANS function (heart-rate variability and vascular indices; MaxPulse Medicore).
Questionnaires on sleep quality, physical activity, and weight-management self-efficacy.
Visits and duration. 6-month participation with baseline, 3-weekly check-ins, and a final visit for repeat testing and blood sampling.
Outcomes. The study focuses on safety and on whether Urolithin A, compared with placebo, helps preserve functional muscle mass and improves mitochondrial, inflammatory, and metabolic biomarkers during weight loss.
Who can join. Adults 30-60 years with obesity and higher visceral fat who are willing to follow the lifestyle program. Key medical exclusions (e.g., diabetes, active autoimmune disease, pregnancy) and supplement restrictions apply; full criteria are provided in the Eligibility section.
Potential benefits and risks. Participants may benefit from weight loss support and close monitoring. Risks include blood draw discomfort and potential, usually mild, supplement-related side effects. Safety will be monitored throughout.
Location and sponsor. The study is conducted at Charles University, Faculty of Medicine in Hradec Králové (Czech Republic) under the Department of Preventive Medicine.
Scientific Background and Rationale
Obesity and aging share pathophysiological features-mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and chronic low-grade inflammation-that contribute to loss of skeletal muscle and functional capacity ("sarcopenic obesity") and increased frailty risk. While weight reduction improves cardiometabolic health, it can also decrease lean mass if not carefully managed.
Urolithin A (UA) is a bioactive metabolite derived from ellagitannins that has shown the ability to activate mitophagy, support mitochondrial function, and favor muscle health in preclinical and early clinical studies. We hypothesize that, when combined with a standardized lifestyle program, UA 500 mg/day will preserve functional muscle mass and favorable biomarker profiles during intentional weight loss in adults with obesity.
Objectives
Primary objective:
Evaluate the safety and efficacy of 6 months of Urolithin A 500 mg once daily versus placebo, in addition to a structured lifestyle program, in adults with obesity undergoing dietary restriction. Efficacy focuses on preservation of functional muscle mass in the context of weight loss and on improvements in biomarkers of mitochondrial function, inflammation, and metabolic health.
Key secondary objectives:
Quantify changes in body composition (skeletal muscle mass; visceral adiposity) over time.
Assess muscle strength and endurance (handgrip dynamometry; 30-second chair-stand).
Evaluate systemic inflammatory and oxidative-stress markers and metabolic profile (e.g., lipids, glucose/HbA1c, CRP).
Explore the impact on biological aging using validated epigenetic aging and related molecular biomarkers.
Characterize changes in autonomic/vascular indices (e.g., HRV, arterial elasticity) and patient-reported outcomes (sleep, activity, weight-management self-efficacy).
Examine associations between lifestyle adherence and outcomes.
Study Design
Prospective, single-center, randomized, placebo-controlled, parallel-group clinical trial with blinded participants, investigators, and outcome assessors. Target enrollment: \~100 participants (approximately balanced by sex and age group ≤45 vs ≥45 years via stratified randomization).
Arms and Interventions
Experimental (Urolithin A): Urolithin A 500 mg oral capsule once daily for 24 weeks.
Control (Placebo): Matching placebo capsule once daily for 24 weeks.
Co-intervention (both arms): A standardized lifestyle program tailored to baseline anthropometrics, comprising:
Energy restriction with higher protein intake (approx. 1.0-1.5 g/kg/day) and reduced carbohydrates; emphasis on minimally processed foods.
Time-restricted eating: 11-hour eating window with 13-hour overnight fast (e.g., \~08:00-19:00).
Sleep-hygiene optimization: regular bed/wake times; targets of 7.5-9 hours of nightly sleep; guidance on environment, light exposure, stimulants, and pre-sleep routines.
Light daily activity guidance. Use of other dietary supplements is prohibited during participation.
Schedule of Assessments
Screening / "Visit 0": Eligibility review; bioimpedance to confirm visceral fat level threshold; anthropometry; blood pressure.
Baseline (Day 0): Informed consent; questionnaires; blood sampling; bioimpedance (InBody); MaxPulse Medicore autonomic/vascular testing; muscle strength (handgrip dynamometry, average of 3 trials + peak value) and muscle endurance (30-second chair-stand); individualized nutrition and sleep-hygiene education.
Follow-ups: Approximately every 3 weeks-anthropometry, blood pressure, bioimpedance, MaxPulse Medicore, muscle testing, adherence review, and lifestyle adjustments as needed.
End of Study (Week 24): Repeat baseline assessments and final blood sampling; exit interview.
Outcome Domains (entered in detail in the Outcomes module)
Functional muscle preservation: bioimpedance-derived skeletal muscle indices; handgrip strength; chair-stand repetitions.
Body composition: total fat mass; visceral adipose area/score; segmental lean/fat distribution.
Cardiometabolic/Inflammatory biomarkers: standard biochemistry (electrolytes, liver/kidney function, lipids, glucose/HbA1c, CRP) and exploratory panels (e.g., TNF-α, IL-6, adipokines, myostatin, SIRT1, endothelial adhesion molecules).
Mitochondrial/healthy aging measures: DNA-based epigenetic aging clocks and related molecular markers from whole blood.
Autonomic/vascular function: HRV metrics, arterial elasticity, and vascular flow indices via MaxPulse Medicore.
Patient-reported outcomes: sleep quality (PSQI), physical activity (GPAQ), and weight-management self-efficacy (WEL).
Eligibility (summary; see Eligibility module for full criteria)
Adults 30-60 years with BMI >30 kg/m² and elevated visceral fat by bioimpedance who can follow the lifestyle program. Key exclusions include thyroid disease, type 2 diabetes, autoimmune/inflammatory bowel disease, active malignancy, pregnancy/lactation or planned pregnancy, severe psychiatric disease limiting adherence, major uncontrolled comorbidities, significant musculoskeletal limitations, and use of dietary supplements other than the study product.
Randomization, Blinding, and Allocation Concealment
Participants will be randomized 1:1 to UA or placebo using a computer-generated sequence with stratification by sex and age. Identical capsules will be dispensed to maintain blinding of participants, site staff, and assessors. Emergency unblinding procedures will be in place.
Safety Monitoring
Adverse events (AEs), vitals, and laboratory parameters will be collected at each visit. Women of child-bearing potential will follow pregnancy precautions; pregnancy during the study leads to discontinuation of the investigational product and withdrawal from the trial. Pre-specified stopping rules include serious or unexpected adverse reactions deemed related to the study product. AEs/SAEs will be recorded and reported per applicable regulations.
Concomitant Medications and Prohibited Therapies
Stable chronic medications are permitted when clinically necessary; major changes (e.g., for hypertension) are allowed only as needed and will be documented. All non-study dietary supplements are prohibited during participation.
Adherence and Retention
Adherence will be supported through structured education, 3-weekly check-ins, and review of pill counts and lifestyle logs (nutrition, sleep, activity). Motivational elements include a brief written statement of goals at baseline.
Biospecimen Handling
Blood samples will be pseudonymized and processed according to standard operating procedures for clinical chemistry/hematology, ELISA panels (inflammation, adipokines, etc.), and DNA extraction for epigenetic analyses. Samples will be delivered to designated laboratories within defined processing windows.
Statistical Considerations
Analyses will follow intention-to-treat with a per-protocol sensitivity set. Continuous outcomes will be analyzed using ANCOVA or mixed-effects models with baseline values and stratification factors as covariates. Categorical outcomes will use appropriate models (e.g., χ² or logistic regression). Pre-specified subgroup analyses by sex and age group will be performed. With \~100 participants, the study is powered to detect a moderate effect size in body-composition/functional endpoints while characterizing safety and biomarker trajectories.
Ethics and Oversight
The protocol will receive Ethics Committee/IRB approval prior to enrollment. The trial will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All participants will provide written informed consent. Data confidentiality will be maintained using coded identifiers and secure storage.
Expected Impact
If effective, Urolithin A could provide a simple, adjunctive strategy to protect muscle health and improve biological aging and metabolic markers during dietary weight loss in adults with obesity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Placebo
Dietary Supplement: Urolithin A 500mg
Dietary Supplement: Urolithin A (500 mg) - Intervention Description Oral Urolithin A 500 mg capsule once daily for 24 weeks, preferably with the first meal. GMP-manufactured product; identical capsule shell/appearance to placebo. No dose titration. No other dietary supplements allowed during participation. Adherence assessed by pill counts and visit logs; temporary interruption permitted for adverse events per protocol. Co-administered with the same standardized lifestyle program as the control arm.
Placebo Comparator: Matching Placebo - Intervention Description Matching inert capsule (no Urolithin A), same size, color, shell, and packaging as active product; once daily for 24 weeks with the first meal. Dispensed in coded kits to maintain masking. Participants receive the same lifestyle program as the active arm. Use of other dietary supplements is prohibited during the trial.
Change in Appendicular Skeletal Muscle Index (ASMI) by Bioimpedance
ASMI = sum of lean mass in both arms and legs (kg) divided by height² (m²), derived from segmental bioimpedance (InBody). Primary comparison is change from baseline to Week 24 between Urolithin A and placebo using ANCOVA adjusting for baseline, sex, and age stratum. Higher ASMI reflects greater functional muscle mass.
Time frame: Baseline to Week 24 (end of intervention)
Change in Handgrip Strength (kg)
Dominant-hand grip strength measured with a calibrated handheld dynamometer; average of 3 trials (peak also recorded). Between-group difference in change from baseline to Week 24.
Time frame: Baseline to Week 24
Change in Visceral Adipose Area (cm²) by Bioimpedance
Visceral fat area (VFA, cm²) from InBody bioimpedance. Lower values indicate improvement. Between-group difference in change from baseline to Week 24.
Time frame: Baseline to Week 24
Change in Percent Body Fat (%)
Whole-body fat percentage by bioimpedance (InBody). Between-group difference in change from baseline to Week 24.
Time frame: Baseline to Week 24
Glycemic Control (HbA1c)
Change from baseline in HbA1c (%). Between-group difference (Urolithin A vs placebo) in change to Week 24 (ANCOVA with baseline, sex, age stratum).
Time frame: Baseline to Week 24
LDL-C
Change from baseline in LDL-C. Between-group difference in change to Week 24.
Time frame: Baseline to Week 24
Inflammation (suPAR)
Change from baseline in systemic inflammatory marker (suPAR; ng/mL). Between-group difference in change to Week 24.
Time frame: Baseline to Week 24
GDF15
Change from baseline in serum GDF15 (assay units). Between-group difference in change to Week 24.
Time frame: Baseline to Week 24
Autonomic/Vascular Function (Arterial Elasticity)
Change from baseline arterial elasticity score (MaxPulse Medicore). Between-group difference in change to Week 24.
Time frame: Baseline to Week 24
Epigenetic Aging Panel (DNA Methylation Age Acceleration)
Change from baseline in blood-based DNA methylation age acceleration (years; difference between DNAm age and chronological age, specifically HorvathClock). Between-group difference in change to Week 24.
Time frame: Baseline to Week 24
Weight-Loss Responder Rates (≥5% and ≥10% Body Weight)
Proportion of participants achieving ≥5% and ≥10% reduction from baseline body weight. Between-group comparison at Week 24.
Time frame: Baseline to Week 24
Patient-Reported Outcomes Panel (WEL)
Change from baseline in Weight Efficacy Lifestyle Questionnaire total score (WEL). Between-group difference in change to Week 24.
Time frame: Baseline to Week 24
Patient-Reported Outcomes Panel (PSQI)
Change from baseline in Pittsburgh Sleep Quality Index total score (PSQI). Between-group difference in change to Week 24.
Time frame: Baseline to Week 24
Patient-Reported Outcomes Panel (GPAQ)
Change from baseline in Global Physical Activity Questionnaire total MET-minutes/week (GPAQ). Between-group difference in change to Week 24.
Time frame: Baseline to week 24
Safety Panel (TEAEs and SAEs)
Participants with treatment-emergent adverse events and serious adverse events, coded by SOC/PT; severity and relatedness summarized by arm.
Time frame: From first dose to Week 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Aug 2026, 10 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 10 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Feb 2027, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Urolithin A Supplement
Charles University, Czech Republic →